Hutchmed (HCM) announced that the new drug application for fanregratinib for the treatment of adult patients with advanced, metastatic or unresectable intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusion/rearrangement who have previously received systemic therapy has been accepted and granted priority review by the China National Medical Products Administration.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCM: